RICHMOND, Virginia and ROSH HAAYIN, Israel, April 2 /PRNewswire/ -- The Virginia Biosciences Commercialization Center (VBCC) recently announced the newest company to establish their U.S. office at the Virginia BioTechnology Research Park as a member of the VBCC program, EnzySurge, an Israeli bioscience company focused on chronic wound management.
"EnzySurge has developed DermaStream(TM) based on its proprietary Continuous Streaming Therapy(TM) (CST) technology. DermaStream(TM) is a comprehensive yet versatile treatment for hard-to-heal chronic wounds throughout the debridement, regeneration and closure phases, designed for hospitals, clinics and home treatment" stated Donna Edmonds, executive director of the VBCC. "We're very excited to support the introduction of this innovative product line to the U.S. market. "Pressure, venous and diabetic wounds are an increasing problem in the United States, with more than 6 million cases reported annually. Each year, more than 2.3 million Americans are treated for diabetes-related skin ulcers and more than 100,000 amputations are performed on diabetic patients due to non-healing wounds."
Treatment of chronic wounds is a costly, long, multi-step process that often requires hospitalization, and is extremely uncomfortable for the patient. The process involves debriding the wound, surgically removing unhealthy tissue, flushing the wound with anti-microbial products and keeping the open wound clear of infection to promote tissue regeneration and hopefully lead to wound closure.
The DermaStream device continuously streams fresh highly active solutions in an isolated, optimally receptive and bacteria-controlled wound environment, thereby provides faster, more effective and comprehensive chronic wound treatment - from wound debridement, through regeneration to closure
"We're dedicated to developing innovative solutions that expedite wound
healing and improve patients' quality of lives," stated Amir S
|SOURCE The Virginia Biosciences Commercialization Center andEnzySurge Ltd.|
Copyright©2008 PR Newswire.
All rights reserved